Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

Yuehui Lin, Defeng Zhao, Biping Deng, Dan Liu, Hong Yan, Biyi Li, Yu Xia, Ruyue Zheng, Tong Wu, Chunrong Tong

Blood (2024) 144 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2024-207659

Published: 2024

Journal Articles

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Na Zhang, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Haifeng Wu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2024-202403

Published: 2024

Journal Articles

Clinical Analysis of CAR-T Cell Therapy in Patients with Relapsed Acute B-Lymphoblastic Leukemia after Second Allogeneic Hematopoietic Stem Cell Transplantation

Hong Yan, Biyi Li, Ruyue Zheng, Yuehui Lin, Lihong An, Biping Deng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7214.

https://doi.org/10.1182/blood-2024-204694

Published: 2024

Journal Articles

Clinical Analysis of Sequential CAR-T Therapy Combined with Demethylating Agents and Personalized Targeted Drugs in 18 Elderly Patients with Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Biyi Li, Hong Yan, Ruyue Zheng, Shuangyou Liu, Yuehui Lin, Lihong An, Biping Deng, Qinlong Zheng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7213.

https://doi.org/10.1182/blood-2024-204670

Published: 2024

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Journal Articles

Clinical Analysis of CAR-T Cell Therapy in Patients with Acute B-Lymphoblastic Leukemia and Central Nervous System Infiltration

Hong Yan, Biyi Li, Ruyue Zheng, Yuehui Lin, Biping Deng, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7215.

https://doi.org/10.1182/blood-2024-204742

Published: 2024

Journal Articles

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Chen Chen, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2024-201274

Published: 2024

Journal Articles

Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy

Ruyue Zheng, Hong Yan, Biyi Li, Yuehui Lin, Shuangyou Liu, Lihong An, Biping Deng, Jun Zhang, Chunrong Tong, Tong Wu, Defeng Zhao

Blood (2024) 144 (Supplement 1): 7212.

https://doi.org/10.1182/blood-2024-204574

Published: 2024

Journal Articles

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Biping Deng, Zhaoli Liu, Xiaoming Qu, Yu'e Zhang, Zhongxin Zhang, Rong Luan, Lingli Zhang, Ming Ma, Xiai Wu, Rui Liu, Alex H. Chang, Kai Hu, Chunrong Tong

Blood (2024) 144 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2024-203423

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Teng Xu, Fan Yang, Rui Liu, Zhonghua Fu, Na Li, Xiaoyan Ke, Shaomei Feng, Biping Deng, Kai Hu

Blood (2023) 142 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2023-185590

Published: 2023

Journal Articles

T Cell Selection Is Not Helpful for Therapeutic Efficacy of CART19 in Relapsed or Refractory B-ALL Patients with Peripheral Blood Leukemia Burden at Time of Apheresis

Biping Deng, Zhaoli Liu, Jing PAN, Shuangyou Liu, Xiaoming Qu, Yu'e Zhang, Lingli Zhang, Ming Ma, Zhongxin Zhang, Xinjian Yu, Qinlong Zheng, Chunrong Tong

Blood (2023) 142 (Supplement 1): 6943.

https://doi.org/10.1182/blood-2023-180359

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

Yue Tan, Jing Pan, Biping Deng, Zhuojun Ling, Song Weiliang, Zhenglong Tian, Ming Cao, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Chunyu Li

Blood (2022) 140 (Supplement 1): 4602–4603.

https://doi.org/10.1182/blood-2022-165819

Published: 2022

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

Ying Liu, Biping Deng, Bo Hu, Wenqun Zhang, Qing Zhu, Yang Liu, Shan Wang, Pei Zhang, Junhan Yang, Qinlong Zheng, Xinjian Yu, Zifen Gao, Chunju Zhou, Wei Han, Alex Hong Chang, Yonghong Zhang

Blood (2021) 138 (Supplement 1): 257.

https://doi.org/10.1182/blood-2021-146302

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Fan Yang, Hui Shi, Yang Lei, Ruiting Li, Teng Xu, Biping Deng, Tong Wu, Xiaoyan Ke, Kai Hu

Blood (2021) 138 (Supplement 1): 557.

https://doi.org/10.1182/blood-2021-146767

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Clinical Analysis of CAR-T Cell Therapy in Patients with Relapsed Acute B-Lymphoblastic Leukemia after Second Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Analysis of Sequential CAR-T Therapy Combined with Demethylating Agents and Personalized Targeted Drugs in 18 Elderly Patients with Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Clinical Analysis of CAR-T Cell Therapy in Patients with Acute B-Lymphoblastic Leukemia and Central Nervous System Infiltration

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

T Cell Selection Is Not Helpful for Therapeutic Efficacy of CART19 in Relapsed or Refractory B-ALL Patients with Peripheral Blood Leukemia Burden at Time of Apheresis

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only